![](/a/web/gR9jCyVhjWy3vxeZJRweL4/8WgNBa/tehrlich.jpg)
Timothy H. Ehrlich
Tim is a partner in our Boston office and is chair of the firm's Life Sciences practice group.
Tim represents start-up, emerging growth and public life science companies in the biotechnology, pharmaceutical, medical device, diagnostics and healthcare IT industries. His practice spans the entire corporate lifecycle, from formation through liquidity, and he regularly serves as principal outside or general counsel to his clients. Tim is broadly experienced in business formation and entity selection, deal structuring, equity and debt financing transactions, general corporate and governance matters, M&A events and public offerings. Tim also has particular expertise in structuring and negotiating strategic alliances, including “bet-the-company” intellectual property collaborations and joint ventures, and providing strategic counseling and advice regarding intellectual property protection and commercialization. In addition to his company client counsel, Tim represents venture capital funds and institutional investors in their life science financing activities.
Tim has spoken in numerous forums and authored articles on corporate structuring and capital raising, technology licensing and intellectual property matters and related business strategies that affect strategic alliances. He is also a co-author of the treatise “Corporate Partnering, Structuring and Negotiating Domestic and International Strategic Alliance” (Aspen Publishers).
Tim has been an advisor to the Harvard Law Entrepreneurship Program at Harvard Law School and the Harvard University iLab since their inception. In addition, Tim is a founder and director of Gursha, Inc., a charitable organization dedicated to supporting underserved children in Ethiopia. He is also a board member of Community Rowing Inc., a non-profit organization dedicated to creating opportunities for people of all backgrounds, abilities, and experience to grow through the sport of rowing.
Tim received his J.D., cum laude, from Harvard Law School, where he was an editor of the Harvard Journal of Law and Technology. He received an A.B., summa cum laude, from Princeton University, where he was elected to Phi Beta Kappa, selected as a national finalist for the Rhodes Scholarship, and was a four-year member of the 1993 national championship varsity squash team.
Before entering private practice, Tim served as a law clerk to the Honorable Thomas Penfield Jackson of the United States District Court in Washington, D.C., where he was primarily responsible for the case of US v. Microsoft.
Numerous industry groups and publications have recognized Tim as a national leader for his corporate and transactional work. LMG Life Sciences has named Tim a “Life Sciences Star” every year since 2012, has named him a nominee for its “VC Lawyer of the Year” award in 2020 and 2021 and awarded the firm the “VC Firm of the Year” honors in 2022.
Webinar
Tracking the Lifecycle of Affinivax
Gunderson Dettmer hosted the Tackling the Lifecycle of Affinivax: From Inception to Exit webinar to discuss Affinivax’s trajectory from an early-stage vaccine start-up to its $3.3 billion acquisition by GSK. Gunderson Dettmer partner Tim Ehrlich, Affinivax CEO Steve Brugger, Affinivax Chief Business Officer Stuart Chaffee, and J.P. Morgan Global Chairman Philip Ross led the webinar and shared insights about Affinivax’s acquisition.